Type: Press Release
… heart support technologies today reported second quarter fiscal 2021 revenue of $2098 million a sequential increase of 27% compared to Q1 fiscal year 2021 and a year over year … a sequential increase of 29% compared to revenue of $1262 million during Q1 fiscal year 2021 and a decrease of 1% …
Type: Press Release
Abiomed to Showcase Expanded FDA Indications and Next Generation Heart Recovery Products at TCT 2018
… highlight the recently expanded FDA indications for high-risk PCI and cardiogenic shock Initiatives will also highlight Protected PCI’s ability to allow for more complete revascularization which improves outcomes1 and … MD The Impact of The Cardiogenic Shock Initiative (NCSI) One Year Later Navin Kapur MD Understanding the Importance …
Type: Press Release
… support technologies today reported record fourth quarter fiscal 2021 revenue of $2412 million compared to revenue of $2067 million for the same period of … 29 2021 through 1100 am ET on May 6 2021 The replay phone number is (855) 859-2056 the international number is …
Type: Press Release
… patients have been treated with the Impella 55 with SmartAssist heart pump in the first year after the US Food and Drug … multimedia View the full release here https//wwwbusinesswirecom/news/home/20201105005280/en/ The Impella 55 with … giving these critically ill patients a chance at survival” One such patient is 64-year-old Keith Brown After Keith …
Type: Press Release
… Percutaneous Coronary Intervention to improve patient outcomes and quality of life with supported high-risk PCI by utilizing best practices techniques and … need for digital and on-demand medical education” Nearly one million PCI procedures are performed annually in the …
Type: Press Release
… extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more … and hemodynamic support for pediatric patients This press release features multimedia View the full release … the way oxygenation is delivered “Abiomed is the best positioned company to build on the legacy of what we started” said …
Type: Press Release
… today announced that it has received US Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella … to provide treatment of ongoing cardiogenic shock In this setting the Impella heart pumps stabilize the patients … end organs and allow for recovery of the native heart This latest approval adds to the prior FDA indication of …
Type: Press Release
… for the quarter totaled $2481 million an increase of 18% compared to $2098 million during the same period of the prior fiscal year Worldwide Impella® heart pump product revenue for … we made progress on product innovation and regulatory milestones while leveraging our commercial field team …
Type: Press Release
… and support technologies today reported third quarter fiscal 2019 revenue of $2006 million an increase of 30% compared to revenue of $1540 million for the same period of … controlled trial On January 15 2019 the company celebrated one year of Impella use in Japan by hosting a seminar for …
Type: Press Release
… WIRE)--Jun 1 2020-- The United States Food and Drug Administration (FDA) has issued an emergency use authorization … suffering from COVID-19 related right heart failure or decompensation including pulmonary embolism (PE) Abiomed … vasopressor requirements The patient was discharged in one week The existing FDA PMA labeling for Impella RP and …